Article ID Journal Published Year Pages File Type
5816765 Phytomedicine 2012 6 Pages PDF
Abstract
Silymarin (SMN) is used as an antioxidant complex to attenuate the pro-oxidant effects of toxic agents. This study was carried out to investigate the effect of SMN, Celecoxib (CLX) individually and in combination on monoiodoacetate (MIA)-induced osteoarthritis (OA) in rat. Forty adult Wistar rats were assigned to control and test groups. Animals in the test group following OA induction were subdivided into 4 subgroups according to the treatment profile: OA+; received saline normal (5 ml/kg, b.w.), OA+CLX+; received CLX (100 mg/kg, orally), OA+SMN+, received SMN (50 mg/kg, orally), and OA+CLX+SMN+, received both CLX and SMN. The animals received test compounds by gastric gavage for 14 consecutive days. Animals in the OA+ group showed a significant (p < 0.01) increase in serum and synovial levels of IL-1β, while both test compounds reduced the IL-1β level. Both CLX and SMN lowered the OA-increased level of malondialdehyde by 77% and 79% and nitric oxide by 73% and 76%, respectively, in the synovial tissue. Special safranin O (SO) histopathological staining revealed that CLX and SMN improved the MIA-induced destruction and fibrillation in cartilage surface. CLX and SMN regulated the MIA-up regulated IL-1β at mRNA level. The combination therapy resulted in an additive effect between CLX and SMN in biochemical, histopathological and molecular assays. These findings suggest that SMN exerts anti-inflammatory effect and also potentiates the anti-inflammatory effect of CLX on MIA-induced OA. The anti-inflammatory property of SMN may attribute to its antioxidant capacity, which affects the proinflammatory mediators at translational and transcriptional level.
Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Clinical Biochemistry
Authors
, , , , ,